Horizon Investments LLC Acquires 59,618 Shares of AbbVie Inc. $ABBV

Horizon Investments LLC raised its holdings in AbbVie Inc. (NYSE:ABBV) by 74.5% in the fourth quarter, Holdings Channel reports. The firm owned 139,641 shares of the company’s stock after purchasing an additional 59,618 shares during the period. Horizon Investments LLC’s holdings in AbbVie were worth $31,652,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock valued at $41,306,353,000 after purchasing an additional 3,032,438 shares during the period. Legal & General Group Plc grew its stake in AbbVie by 4.3% in the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after purchasing an additional 493,420 shares during the period. Wellington Management Group LLP grew its stake in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Amundi grew its stake in AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after purchasing an additional 1,414,621 shares during the period. Finally, Ameriprise Financial Inc. grew its stake in AbbVie by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock valued at $2,241,363,000 after purchasing an additional 408,426 shares during the period. Institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on ABBV shares. Cantor Fitzgerald restated an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a research note on Thursday. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Piper Sandler reduced their price objective on AbbVie from $299.00 to $294.00 and set an “overweight” rating for the company in a research note on Thursday, April 23rd. The Goldman Sachs Group restated a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Finally, Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target on the stock in a research report on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $252.90.

AbbVie Stock Performance

Shares of ABBV opened at $206.63 on Friday. The stock’s 50-day simple moving average is $214.55 and its 200 day simple moving average is $221.60. The stock has a market capitalization of $365.36 billion, a price-to-earnings ratio of 101.79, a price-to-earnings-growth ratio of 0.76 and a beta of 0.38. AbbVie Inc. has a 52-week low of $176.57 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.46 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.21 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s dividend payout ratio is 340.89%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.